Cargando…
Oxidant/antioxidant imbalance is an inherent feature of depression
BACKGROUND: 50% to 60% of the people who have recovered from the first episode of depression experience a relapse. The immune system of the people suffering from depression is in a permanent state of pathological pro-inflammatory readiness. There are some reports that depressive episodes cause sensi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392866/ https://www.ncbi.nlm.nih.gov/pubmed/25880127 http://dx.doi.org/10.1186/s12888-015-0454-5 |
_version_ | 1782366058222452736 |
---|---|
author | Talarowska, Monika Szemraj, Janusz Berk, Michael Maes, Michael Gałecki, Piotr |
author_facet | Talarowska, Monika Szemraj, Janusz Berk, Michael Maes, Michael Gałecki, Piotr |
author_sort | Talarowska, Monika |
collection | PubMed |
description | BACKGROUND: 50% to 60% of the people who have recovered from the first episode of depression experience a relapse. The immune system of the people suffering from depression is in a permanent state of pathological pro-inflammatory readiness. There are some reports that depressive episodes cause sensitization of immune-inflammatory pathways and that staing of depression (e.g. number of depressive episodes) is correlated with immune-inflammatory markers. The main objective of the study was to delineate whether recurrent major depression (rDD) is characterized by alterations in selected immune-inflammatory biomarkers as compared with first episode of depression (ED-I), i.e. expression of mRNA and enzymatic activity of manganese superoxide dismutase (MnSOD, SOD-2), myeloperoxidase (MPO), inducible nitric oxide synthase (iNOS, NOS-2), and cyclooxygenase-2 (COX-2). METHODS: The study was carried out in a group of 131 patients: ED-I group – 42 patients, rDD group – 89 patients. Depression severity was assessed with the 17-item Hamilton Depression Rating Scale (HDRS). The number of depression episodes and the disease duration periods were recorded in each patient. For the patients, HDRS was administered at admission during the symptomatic phase, which would generally be either before or shortly after modification of the previous antidepressant drug regimen. Reassessment of the mental condition was conducted after 8 weeks of the pharmacological treatment also with the use of the HDRS scale. RESULTS: No significant statistical differences were found between the analysed groups as regards the intensity of depressive disorders. No differences in the expression of MnSOD, MPO, COX-2 and i-NOS genes on the level of both mRNA and protein were observed between both groups. No significant interrelation was noticed between the number of depression episodes experienced and the expression of selected genes on the mRNA level and protein level. CONCLUSIONS: There is no significant difference in MnSOD, MPO, COX-2 and i-NOS between patients with recurrent depressive disorders and those in a first episode of depression. These findings suggest that these enzymes are trait markers of depression and are not related to staging of depression. |
format | Online Article Text |
id | pubmed-4392866 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43928662015-04-11 Oxidant/antioxidant imbalance is an inherent feature of depression Talarowska, Monika Szemraj, Janusz Berk, Michael Maes, Michael Gałecki, Piotr BMC Psychiatry Research Article BACKGROUND: 50% to 60% of the people who have recovered from the first episode of depression experience a relapse. The immune system of the people suffering from depression is in a permanent state of pathological pro-inflammatory readiness. There are some reports that depressive episodes cause sensitization of immune-inflammatory pathways and that staing of depression (e.g. number of depressive episodes) is correlated with immune-inflammatory markers. The main objective of the study was to delineate whether recurrent major depression (rDD) is characterized by alterations in selected immune-inflammatory biomarkers as compared with first episode of depression (ED-I), i.e. expression of mRNA and enzymatic activity of manganese superoxide dismutase (MnSOD, SOD-2), myeloperoxidase (MPO), inducible nitric oxide synthase (iNOS, NOS-2), and cyclooxygenase-2 (COX-2). METHODS: The study was carried out in a group of 131 patients: ED-I group – 42 patients, rDD group – 89 patients. Depression severity was assessed with the 17-item Hamilton Depression Rating Scale (HDRS). The number of depression episodes and the disease duration periods were recorded in each patient. For the patients, HDRS was administered at admission during the symptomatic phase, which would generally be either before or shortly after modification of the previous antidepressant drug regimen. Reassessment of the mental condition was conducted after 8 weeks of the pharmacological treatment also with the use of the HDRS scale. RESULTS: No significant statistical differences were found between the analysed groups as regards the intensity of depressive disorders. No differences in the expression of MnSOD, MPO, COX-2 and i-NOS genes on the level of both mRNA and protein were observed between both groups. No significant interrelation was noticed between the number of depression episodes experienced and the expression of selected genes on the mRNA level and protein level. CONCLUSIONS: There is no significant difference in MnSOD, MPO, COX-2 and i-NOS between patients with recurrent depressive disorders and those in a first episode of depression. These findings suggest that these enzymes are trait markers of depression and are not related to staging of depression. BioMed Central 2015-04-08 /pmc/articles/PMC4392866/ /pubmed/25880127 http://dx.doi.org/10.1186/s12888-015-0454-5 Text en © Talarowska et al.; licensee BioMed Central. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Talarowska, Monika Szemraj, Janusz Berk, Michael Maes, Michael Gałecki, Piotr Oxidant/antioxidant imbalance is an inherent feature of depression |
title | Oxidant/antioxidant imbalance is an inherent feature of depression |
title_full | Oxidant/antioxidant imbalance is an inherent feature of depression |
title_fullStr | Oxidant/antioxidant imbalance is an inherent feature of depression |
title_full_unstemmed | Oxidant/antioxidant imbalance is an inherent feature of depression |
title_short | Oxidant/antioxidant imbalance is an inherent feature of depression |
title_sort | oxidant/antioxidant imbalance is an inherent feature of depression |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392866/ https://www.ncbi.nlm.nih.gov/pubmed/25880127 http://dx.doi.org/10.1186/s12888-015-0454-5 |
work_keys_str_mv | AT talarowskamonika oxidantantioxidantimbalanceisaninherentfeatureofdepression AT szemrajjanusz oxidantantioxidantimbalanceisaninherentfeatureofdepression AT berkmichael oxidantantioxidantimbalanceisaninherentfeatureofdepression AT maesmichael oxidantantioxidantimbalanceisaninherentfeatureofdepression AT gałeckipiotr oxidantantioxidantimbalanceisaninherentfeatureofdepression |